To the full analysis
National HealthCare stock: growth
NHCNational HealthCare reported $1.52B in revenue for fiscal 2025, up 16.9% on the prior year, up 9.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.4%
per year from 2006 to 2025, per share 4.1%
Earnings (Annual rate)
6.4%
per year from 2006 to 2025, per share 5.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 9.1% | 5.3% | 5.4% |
| Revenue per share | 8.9% | 4.2% | 4.1% |
| Earnings | 23.4% | 8.5% | 6.4% |
| Earnings per share | 23.1% | 8.8% | 5.1% |
| Free cash flow | −3.9% | 25.3% | no data |
| Free cash flow per share | −4.1% | 24.0% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $562.96M | $36.74M | −$1.67M |
| 2007 | $598.03M | $45.45M | $28.17M |
| 2008 | $633.21M | $36.37M | $14.22M |
| 2009 | $668.22M | $40.05M | $41.09M |
| 2010 | $720.65M | $52.7M | $29.57M |
| 2011 | $773.24M | $64.99M | $57.06M |
| 2012 | $761M | $59.3M | $42.69M |
| 2013 | $788.96M | $64.61M | $58.91M |
| 2014 | $871.68M | $53.37M | $22.4M |
| 2015 | $906.62M | $53.14M | $15.55M |
| 2016 | $923.58M | $50.54M | $28.28M |
| 2017 | $963.9M | $56.21M | $62.12M |
| 2018 | $980.35M | $58.96M | $68.66M |
| 2019 | $996.38M | $68.21M | $73.7M |
| 2020 | $980.71M | $41.87M | $181.39M |
| 2021 | $1.01B | $138.59M | $23M |
| 2022 | $1.07B | $22.45M | −$21.46M |
| 2023 | $1.14B | $66.8M | $83.32M |
| 2024 | $1.3B | $101.93M | $79.7M |
| 2025 | $1.52B | $120.02M | $148.63M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.